Disclosed are antagonists for the CC chemokine receptor 2 (CCR2) according to formula (I), wherein the substituents are as described within the specification. Further disclosed is the use of said antagonists in the manufacture of a medicament for treating inflammatory diseases, pain diseases, diabetes mellitus, peripheral atherosclerotic disease and diabetic nephropathy.